Searched for
KEYTRUDA BIOSIMILAR
Cipla Q2 net profit falls 35% to Rs 878 crore, revenue dips 2%Cipla reported a 35% year-on-year decline in second-quarter net profit to Rs 878 crore, with revenue and EBITDA also falling amid weaker No...- Cipla Q2 Results: Profit falls 35% YoY to Rs 878 crore; revenue slips 2%Cipla reported a 35% drop in consolidated net profit for Q2FY27, which stood at Rs 878 crore. The company also experienced a 2.4% year-on-y...
- Zydus moves closer to US market for Keytruda biosimilar as FDA accepts applicationZydus Lifesciences has received acceptance for its application regarding the biosimilar of Keytruda, which is a major cancer drug. The USFD...
- Lupin gets USFDA approval for Modafinil tablets to treat excessive sleepinessPharmaceutical major Lupin announced its USFDA approval for Modafinil tablets. These tablets are used to treat excessive sleepiness in adul...
- Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilarCipla said its US unit has entered an exclusive partnership with China’s Qilu Pharmaceutical to license QL2107, a biosimilar of Merck’s can...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Biopharma Shakti: India targets China dependence, patent cliffIndia is launching a major initiative to boost its biopharmaceutical manufacturing. This plan aims to reduce reliance on China for crucial ...
- Sun Pharma places non-binding offer for US-based Organon in its boldest global bet everSun Pharmaceutical Industries Ltd has submitted a non-binding offer to acquire US-based Organon for an all-cash deal, securing $10-14 billi...
- Sun Pharma looks to rise in US with $10 billion Organon buyIndia's largest drugmaker, Sun Pharma, is considering a major acquisition. The company is evaluating the purchase of US-based Organon, a sp...
- Biocon Biologics to introduce three new biosimilars for cancer treatmentBiocon Biologics will launch three new oncology biosimilars. These include Trastuzumab/Hyaluronidase, Nivolumab, and Pembrolizumab. The com...
- Dr Reddy’s, Alvotech to co-develop Keytruda biosimilarDr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of Keytruda, a high...
- Dr. Reddy’s shares rise over 1% on strategic collaboration with Alvotech for Keytruda BiosimilarDr. Reddy’s Laboratories has partnered with global biotech firm Alvotech to co-develop and commercialize a biosimilar of Keytruda (pembroli...
- Stocks in news: SpiceJet, JSW Energy, Bajaj Finserv, IREDA, Coal IndiaIndian stock markets are showing signs of recovery. SpiceJet is dealing with an insolvency tribunal matter. JSW Energy has commissioned a r...
- Dr Reddy's, Alvotech join hands to develop biosimilar for cancer treatmentDr. Reddy's Laboratories has partnered with Alvotech to co-develop and commercialize a biosimilar for pembrolizumab (Keytruda), a crucial c...
- Dr Reddy’s shares climb over 4% after Keytruda biosimilar deal with AlvotechDr. Reddy’s shares rose over 4% after announcing a global biosimilar partnership with Alvotech for Keytruda. Q4FY25 profit rose 22% YoY to ...
- Big chase for a cancer drug: The urgent need for affordable Keytruda alternativesKeytruda, a cancer treatment drug, has achieved $25 billion in global sales. Its mechanism boosts the immune system to fight cancer. In Ind...
- Will Biocon's foray into biosimilar boost its bottomline?Biological drugs are harvested from living organisms or certain components of living organisms. These drugs are very specific and highly ef...
- Boehringer Ingelheim not for immuno therapy drugsA patient of a recently introduced immuno therapy drug is former US President Jimmy Carter who was treated with the drug Keytruda of Merck ...
Load More
